It is with great pleasure that the Division of Gastroenterology and Hepatology at Stanford University School of Medicine announces Stanford Medicine Symposium on HBV and HDV in honor of Dr. Peter Gregory. Dr. Gregory is Professor Emeritus in the Division who has led an illustrious career as an academic leader in medicine, as a hepatologist, and as a clinical investigator in liver disease and viral hepatitis.1-3
In honoring his achievements and celebrating recent progresses in viral hepatitis therapeutics, the Division has put together an outstanding group of international faculty with expertise ranging from basic virology to clinical trials and health policy. The timing of the event is such that it is juxtaposed against the Liver Meeting, the annual meeting of the American Association for the Study of Liver Disease, which will take place in San Francisco on November 9-13.
The program consists of a morning session in hepatitis delta virus (HDV) with the remainder of the day dedicated to hepatitis B virus (HBV). HDV, occurring exclusive in patients with HBV infection, significantly accelerates the progression of liver disease and heightens the risk of hepatocellular carcinoma. In contrast to HBV and hepatitis C virus, there is no approved, effective antiviral treatment directed against HDV to date. However, there has been exciting development in the diagnostic and therapeutic options for patients with HDV infection.
Since the introduction of potent reverse transcriptase inhibitors for HBV, there has been a dramatic improvement in the outcome of patients with chronic HBV infection. Recently, energized by the ground-breaking successes in HCV therapy, researchers have developed compounds designed to clear HBsAg and produced exciting data that the so-called functional cure may be possible in the relatively near future.
We are delighted to feature our Keynote Speaker, Professor Henry LY Chan at the Chinese University of Hong Kong, who will present ‘Definitions and biomarkers of HBV Cure.’ The prospect of HBV cure inspires clinicians and public health officials to work towards the goal set by the World Health Organization to eliminate the global burden of HBV by 2030.
Thanks to our sponsors, registration for this conference is complimentary. We look forward to seeing you at the conference.